IL327480A - Methods for treating macular degeneration - Google Patents

Methods for treating macular degeneration

Info

Publication number
IL327480A
IL327480A IL327480A IL32748026A IL327480A IL 327480 A IL327480 A IL 327480A IL 327480 A IL327480 A IL 327480A IL 32748026 A IL32748026 A IL 32748026A IL 327480 A IL327480 A IL 327480A
Authority
IL
Israel
Prior art keywords
methods
macular degeneration
treating macular
treating
degeneration
Prior art date
Application number
IL327480A
Other languages
Hebrew (he)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IL327480A publication Critical patent/IL327480A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL327480A 2023-10-02 2024-10-02 Methods for treating macular degeneration IL327480A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363587230P 2023-10-02 2023-10-02
PCT/IB2024/059630 WO2025074268A1 (en) 2023-10-02 2024-10-02 Methods for treating macular degeneration

Publications (1)

Publication Number Publication Date
IL327480A true IL327480A (en) 2026-05-01

Family

ID=93211862

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327480A IL327480A (en) 2023-10-02 2024-10-02 Methods for treating macular degeneration

Country Status (3)

Country Link
AU (1) AU2024354759A1 (en)
IL (1) IL327480A (en)
WO (1) WO2025074268A1 (en)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
JPS61502932A (en) 1984-05-25 1986-12-18 デイナ−フア−バ−・キヤンサ−・インステイテユ−ト LTR vector, manufacturing method and usage
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
WO1989007150A1 (en) 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
US5112767A (en) 1988-03-04 1992-05-12 University Of Southern California Vectors with enhancer domains
US6677311B1 (en) 1988-07-20 2004-01-13 The Salk Institute For Biological Studies Inducible HSV-TK in transformed cell populations
JP3082204B2 (en) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ Recombinant retrovirus with an amphotropic and ecotropic host range
WO1990002797A1 (en) 1988-09-15 1990-03-22 North Carolina State University Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
EP0471796A4 (en) 1989-05-10 1993-05-05 Sloan Kettering Institute For Cancer Research Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter
WO1992005266A2 (en) 1990-09-21 1992-04-02 Viagene, Inc. Packaging cells
EP0556345B2 (en) 1990-10-31 2005-10-12 Cell Genesys, Inc. Retroviral vectors useful for gene therapy
US5122767A (en) 1991-01-10 1992-06-16 Northern Telecom Limited Saw device tapped delay lines
DE69131908T3 (en) 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. VIRUS PARTICLES WITH A CHANGED HOSTEL
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP2004536572A (en) 2001-02-23 2004-12-09 セル・ジェネシス・インコーポレイテッド New vector construct
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
WO2009032148A1 (en) 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
EP2252317B1 (en) * 2008-02-15 2014-04-09 Tufts University Treatment of macular degeneration
WO2012021891A2 (en) * 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of complement-related disorders
KR20240107156A (en) * 2021-11-19 2024-07-08 얀센 바이오테크 인코포레이티드 Method for treating geographic atrophy using gene therapy vector expressing soluble CD59

Also Published As

Publication number Publication date
WO2025074268A1 (en) 2025-04-10
AU2024354759A1 (en) 2026-05-14

Similar Documents

Publication Publication Date Title
IL304275A (en) Methods for treating cancer
IL312680A (en) Methods for treating cancer
EP3697920A4 (en) Compositions and methods for treating age-related macular degeneration
IL267146A (en) Novel method of treating macular degeneration
EP4259129A4 (en) Compositions for treating dry age-related macular degeneration (amd)
EP3672579A4 (en) Compositions and methods for treating age-related macular degeneration and geographic atrophy
EP4363057A4 (en) Methods for treating depressive states
SMT202500493T1 (en) Methods for treating hyperphenylalaninemia
IL277779A (en) Compositions and methods for treating macular dystrophy
IL280800A (en) Method for treating pancreatic cancer
GB202107880D0 (en) Method
ZA201904051B (en) Peptide for treating age-related macular degeneration
PL4048284T4 (en) Method for treating cancers
IL308393A (en) Antibodies for treating alpha-synucleinopathies
EP4382103A4 (en) Method for treating retinal degeneration
IL284668A (en) Methods for treating schizophrenia
CA3306613A1 (en) Methods for treating macular degeneration
IL213550A0 (en) Method for treating macular degeneration
IL318067A (en) Therapeutic compositions and methods for age-related macular degeneration
HK40106139A (en) Method for treating retinal degeneration
EP4400576A4 (en) Method for treating cells
IL290351A (en) Compositions and methods for treating neurological diseases
KR102593936B9 (en) Composition for treating macular degeneration comprising novel peptides
SG11202112052VA (en) Compositions and methods for treating presbyopia
EP4051437A4 (en) Method for process water treatment